The Medical Advisor

A peer-reviewed study published in May 2025 in Case Reports in Oncology details three stage IV cancer patients—diagnosed with breast, prostate, and melanoma—who achieved complete or near-complete remission primarily through fenbendazole (FBZ) therapy. No traditional chemotherapy. No experimental mRNA vaccines costing hundreds of thousands of dollars. Just this affordable anti-parasitic drug, combined with basic supplements, leading to sustained cancer-free outcomes: three years for an 83-year-old woman, two years for a 75-year-old man, and nearly one year for a 63-year-old with melanoma. This fenbendazole cancer study challenges conventional oncology, highlighting the potential of repurposed drugs for advanced cancer treatment. Yet, amid growing interest in fenbendazole for cancer, regulatory hurdles persist—such as bans in parts of Canada—raising questions about access to low-cost options. Key Findings from the Fenbendazole Stage IV Cancer Study Patient Outcomes : Three self-treated ...

Breast cancer remains one of the most challenging and prevalent malignancies worldwide, with metastatic and treatment-resistant cases posing significant therapeutic hurdles. Conventional treatment options, including chemotherapy, targeted therapies, and immunotherapy, often reach their limits, particularly in advanced stages such as triple-negative breast cancer (TNBC).  For patients with actionable mutations identified through molecular profiling, targeted therapies are the preferred treatment approach. In particular, for estrogen receptor–positive (ER+) breast cancer patients with a low Oncotype DX recurrence score, hormonal therapy alone is often appropriate, as genomic testing indicates a low risk of cancer recurrence and supports de-escalation of more aggressive systemic treatments. The preference for targeted treatments reflects their demonstrated efficacy in improving outcomes in these molecularly defined subgroups, underscoring the importance of comprehensive genomic profil...